# ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

> **NCT04082897** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Niguarda Hospital** · enrollment: 28 (actual)

## Conditions studied

- CLL Transformation

## Interventions

- **DRUG:** Obinutuzumab 25 MG/ML [Gazyva]
- **DRUG:** Atezolizumab 60 MG/ML [Tecentriq]
- **DRUG:** Venetoclax Oral Tablet

## Key facts

- **NCT ID:** NCT04082897
- **Lead sponsor:** Niguarda Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-04
- **Primary completion:** 2026-09
- **Final completion:** 2026-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04082897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04082897, "ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04082897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*